Congress Pauses on Medicare Device Coverage Legislation as Admin. Rolls Out Rapid Access Initiative

Momentum in Congress around Medicare coverage reform for medical devices appears to have slowed following the Administration’s introduction of a new regulatory approach intended to accelerate patient access. While the newly announced RAPID (Regulatory Alignment for Predictable and Immediate Device) pathway signals a meaningful policy shift, the medtech sector continues to argue that legislative action remains essential to ensure long-term, predictable coverage.

In late April 2026, the Centers for Medicare & Medicaid Services (CMS), in coordination with the U.S. Food and Drug Administration (FDA), unveiled the RAPID pathway to address one of the industry’s most persistent challenges: the gap between FDA authorization of innovative devices and Medicare coverage decisions.

The initiative emphasizes earlier and more structured collaboration between CMS and FDA during the clinical development phase. By aligning evidentiary expectations upfront, the program is designed to ensure that data generated for FDA approval can also satisfy Medicare’s coverage requirements potentially eliminating the need for additional post-approval studies.

Under the proposed framework, CMS could begin its national coverage determination (NCD) review process as soon as a qualifying device receives FDA market authorization. In some cases, coverage decisions could be finalized within a matter of weeks rather than months or years, a significant departure from historical timelines that have often delayed patient access.

The pathway is expected to focus on certain FDA-designated breakthrough devices and includes provisions to encourage the inclusion of Medicare-relevant patient populations in clinical trials. The Administration has framed the effort as part of a broader push to streamline regulatory processes and reduce barriers to innovation reaching patients more quickly. 

Addressing a Longstanding Structural Gap 

For years, developers of medical technologies have cited the disconnect between regulatory approval and payer coverage as a major obstacle. Even after FDA clearance or approval, manufacturers frequently face prolonged uncertainty before Medicare determines whether—and under what conditions—a device will be reimbursed. 

Analyses highlighted across policy and legal commentary have pointed to substantial delays in some cases, contributing to slower adoption of new technologies and creating financial risk for innovators. The RAPID pathway is intended to mitigate this issue by integrating coverage considerations much earlier in the development lifecycle. 

Legislative Efforts Lose Immediate Urgency 

Prior to the RAPID announcement, lawmakers had been considering legislative proposals aimed at creating a more automatic or time-bound Medicare coverage pathway for breakthrough devices.  

However, since the Administration’s move, there has been little visible progress on Capitol Hill. 

This relative quiet may reflect a strategic pause as policymakers evaluate whether the new administrative pathway can achieve many of the same objectives that legislation had sought to address. It also underscores a broader dynamic in health policy, where executive branch action can sometimes reshape - or delay - the trajectory of congressional initiatives. 

Industry Response: Supportive but Seeking Permanence 

The Advanced Medical Technology Association (AdvaMed), of which MichBio is a state affiliate, and other industry stakeholders have generally welcomed the RAPID pathway as a constructive step toward improving access. The emphasis on earlier alignment and faster decision-making is consistent with long-standing industry priorities.

At the same time, AdvaMed has continued to underscore the importance of congressional action. From the industry’s perspective, regulatory initiatives - while valuable - do not provide the same level of certainty as statutory policy. Administrative programs can evolve or be rescinded over time, whereas legislation would establish a more durable and predictable framework.

In addition, stakeholders note that the RAPID pathway is likely to apply to a defined subset of devices and may include eligibility criteria that limit its reach. As a result, gaps in coverage timing and predictability could persist for technologies outside the program’s scope.

Looking Ahead 

The introduction of RAPID represents a notable attempt by CMS and FDA to modernize the intersection of device approval and reimbursement. If implemented effectively, it could shorten timelines and reduce uncertainty for both patients and innovators. 

However, the broader policy debate is far from settled. The medtech industry continues to advocate for a complementary legislative solution that would codify faster coverage pathways and ensure consistency across administrations. 

For now, the policy landscape appears to be in a holding pattern - shaped by a new administrative initiative but still awaiting clarity on whether Congress will ultimately step in to formalize a long-term solution.